Background: Thrombosis is a common complication in patients with cancer. Whether thromboprophylaxis could
Abstract
Background: Thrombosis is a common complication in patients with cancer. Whether thromboprophylaxis could benefit patients with cancer is unclear. The aim of this systematic review was to determine the efficacy and safety of thromboprophylaxis in patients with cancer undergoing surgery or chemotherapy.
Methods: We searched the Cochrane Library, EMBASE, MEDLINE, EBSCOhost, and Web of Science for studies published before May 2018 to investigate whether thromboprophylaxis measures were more effective than a placebo in patients with cancer.
Results: In total, 33 trials with 11,942 patients with cancer were identified. In patients with cancer undergoing surgery, the administration of thromboprophylaxis was associated with decreasing trends in venous thromboembolism (VTE) [relative risk (RR) 0.51, 95% confidence interval (CI) 0.32-0.81] and DVT (RR 0.53, 95% CI 0.33-0.87). In patients with cancer undergoing chemotherapy, the administration of thromboprophylaxis reduced the incidences of VTE, DVT, and pulmonary embolism compared with no thromboprophylaxis (RR 0.54, 95% CI 0.40-0.73; RR 0.47, 95% CI 0.31-0.73; RR 0.51, 95% CI 0.32-0.81, respectively). The pooled results regarding major bleeding showed no significant difference between prophylaxis and no prophylaxis in either the surgical or the chemotherapy groups (RR 2.35, 95% CI 0.74-7.52, p = 0.1482, I2 = 0%; RR 1.30, 95% CI 0.93-1.83, p = 0.1274, I2 = 0%, respectively).
Conclusion: Thromboprophylaxis did not increase major bleeding events or the incidence of thrombocytopenia. All-cause mortality was not significantly different between those who received thromboprophylaxis and those who did not. This meta-analysis provides evidence that thromboprophylaxis can reduce the number of VTE and DVT events, with no apparent increase in the incidence of major bleeding in patients with cancer.
PMID: 32215058 [PubMed]
13:55
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:55
In reply to this message
pubmed: caandvteortroorpul
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--cdn.amegroups.cn-journals-amepc-public-system-cco-icon-for-pubmed.jpg Related Articles
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
Chin Clin Oncol. 2019 Oct;8(S1):S26
Authors: Macedo AVS, Ramacciotti E
PMID: 31684735 [PubMed - indexed for MEDLINE]
29 March 2020
11:21
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
11:21
In reply to this message
pubmed: ctoall&ca or conall
Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
Related Articles
Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
J Clin Med. 2020 Mar 25;9(4):
Authors: Kikuchi R, Shah NP, Dent SF
Abstract
Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exposed to these agents. Novel cancer therapies have led to significant improvements in clinical outcomes for breast cancer patients. In this article, we review the current literature on assessing cardiovascular risk of breast cancer therapies and discuss strategies (including pharmacological and lifestyle interventions) to prevent cardiovascular toxicity.
PMID: 32218132 [PubMed - as supplied by publisher]
14:18
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:18
In reply to this message
pubmed: caandvteortroorpul
[Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Related Articles
[Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Z Rheumatol. 2020 Mar 26;:
Authors: Alten R, Mischkewitz M, Stefanski AL, Dörner T
Comments
Post a Comment
اكتب تعليق حول الموضوع